Farther Finance Advisors LLC Has $678,000 Holdings in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Farther Finance Advisors LLC significantly increased its stake in Prestige Consumer Healthcare by 1,070.2% during the second quarter, bringing its holdings to 8,496 shares worth approximately $678,000.
• Despite a net margin of 19.02%, Prestige Consumer Healthcare reported earnings per share of $0.95 for the latest quarter, missing expectations and showing a 6.6% revenue decline year-over-year.
• Analysts have mixed opinions on Prestige Consumer Healthcare, with ratings ranging from a strong sell to a buy, and an average price target of $94.80 for the stock.

Farther Finance Advisors LLC boosted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 1,070.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,496 shares of the company's stock after buying an additional 7,770 shares during the quarter. Farther Finance Advisors LLC's holdings in Prestige Consumer Healthcare were worth $678,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. UMB Bank n.a. boosted its stake in Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company's stock valued at $26,000 after buying an additional 144 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare in the 1st quarter valued at $38,000. Geneos Wealth Management Inc. boosted its stake in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after buying an additional 269 shares in the last quarter. Costello Asset Management INC acquired a new stake in Prestige Consumer Healthcare in the 1st quarter valued at $112,000. Finally, GAMMA Investing LLC boosted its stake in Prestige Consumer Healthcare by 35.9% in the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock valued at $162,000 after buying an additional 496 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $62.94 on Friday. The stock has a 50-day simple moving average of $67.83 and a 200 day simple moving average of $77.67. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. Prestige Consumer Healthcare Inc. has a 12-month low of $61.93 and a 12-month high of $90.04. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of 14.78, a P/E/G ratio of 1.98 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. During the same period last year, the company earned $0.90 EPS. The company's revenue was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. On average, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on PBH shares. Zacks Research lowered Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research note on Thursday, September 4th. Sidoti raised Prestige Consumer Healthcare from a "neutral" rating to a "buy" rating and set a $80.00 price target on the stock in a research note on Wednesday. Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $94.80.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.